Department of Pharmacology, University College London

Dr. Rhoda Au Receives Prestigious Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development

Retrieved on: 
Wednesday, September 20, 2023
Fillit, Cognition, Inauguration, University, Marsha, Alzheimer's Drug Discovery Foundation, Ageing, Neuroscience, MBA, Research, Vanderbilt University, Doctor of Philosophy, Biomarker, Assistant, Boston University Chobanian & Avedisian School of Medicine, Tablet, Biochemistry, Molecular biology, Department of Pharmacology, University College London, Dementia, MD, Patient, Wake Forest University School of Business, Drug development, Biology, Diagnosis, Entrepreneurship, Digital, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, Anatomy, Pharmacology

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has presented Rhoda Au, PhD, MBA, Professor of Anatomy and Neurobiology at the Boston University Chobanian and Avedisian School of Medicine, with the 2023 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development for her pioneering work with digital biomarkers. The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.

Key Points: 
  • The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.
  • Au is the first researcher with work focused on diagnostic technologies to receive the Goodes Prize.
  • Au and her team is used to create digital profiles that can differentiate between people with stable cognition, cognitive decline, and dementia.
  • Au and our past winners today, it is easy to imagine that the next big breakthrough comes right here, through the ADDF and the Goodes Prize."

New Study Reinforces Powerful Benefits of Wild Blueberries on Cardiovascular and Brain Function

Retrieved on: 
Thursday, March 30, 2023
Blood pressure, Taste, Volunteering, Heart, Anthocyanin, The American Journal of Clinical Nutrition, University, Drink, Psychology, Urine, Woman, King's College London, Research, Brain, Associate, Department of Pharmacology, University College London, Polyphenol, 3202, American Journal, Blood, School, Function (mathematics), Micronutrient, Paper, Science and technology in Asia, Memory, News, Interview, Dietary supplement, Toy, Nutrition, LD, Neuroscience, RD, King

ORNONO, Maine, March 30, 2023 /PRNewswire/ -- New research published in the American Journal of Clinical Nutrition further supports that daily consumption of wild blueberries improves episodic memory, executive function, and blood pressure in healthy adults. The 12-week clinical trial called BluFlow, led by Dr. Ana Rodriguez-Mateos, Associate Professor in Nutrition at the Department of Nutritional Sciences of King's College London, and Professor Claire Williams, Chair of Neuroscience in the School of Psychology & Clinical Language Sciences at the University of Reading, investigated the cognitive and vascular benefits of daily wild blueberry consumption in healthy older individuals.

Key Points: 
  • Scientists found that daily wild blueberry supplementation for 12 weeks led to improvements in cognitive and vascular function.
  • Specifically, those who consumed the wild blueberry beverage daily exhibited:
    "In terms of vascular function, our results reinforce what we've found before in younger populations—that consuming wild blueberries improves blood vessel function as well as lowers blood pressure.
  • The BluFlow study results build on a growing body of evidence that consuming wild blueberries has a positive effect on cognitive performance.
  • "It's clear from this study that consuming wild blueberries is beneficial to cognitive function, as well as vascular health.

Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal

Retrieved on: 
Tuesday, January 17, 2023
Neuroimaging, Addiction, Tan, Brain, University, Vagus nerve stimulation, Anesthesiology, Doctor of Philosophy, Trigeminal nerve, Department of Pharmacology, University College London, Tandem, Principal investigator, Chronic pain, Psychiatry, FDA, Research, Trigeminal neuralgia, UTMB, Death, VNS, History, Patient, Behavioural sciences, Howard Brody, Stroke, Analgesic, Cranial nerves, Pain, TNS, Medical University of South Carolina, MUSC, Vagus nerve, Magnetic resonance, Pain management, Medical school, Opioid use disorder, Dentistry, Pharmaceutical industry, Cereal, Medical imaging, Sparrow, Pharmacology

“Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.

Key Points: 
  • “Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.
  • Importantly, neurostimulation therapy will provide a much needed and innovative treatment option over existing opioid analgesics with high risk for misuse, opioid use disorder, and overdose.”
    Amid the opioid epidemic, a treatment chasm has emerged.
  • Countless patients are being encouraged to avoid or discontinue opioid use for acute pain relief and chronic pain conditions for which opioids are a daily necessity.
  • Spark Biomedical developed the Sparrow Therapy System—the first FDA-cleared wearable, non-invasive tAN device for the treatment of opioid withdrawal.

Bia Diagnostics Becomes First Analytical Lab in the State of Vermont to be Licensed for Adult Use Cannabis Testing

Retrieved on: 
Thursday, June 9, 2022
Vermont Agency of Agriculture Food and Markets, Terpene, USDA, Entrepreneurship, Adult, Research, Food, University, VT, Cannabinoid, Cannabis, Mycotoxin, Pesticide, Degenerative disease, Growth, Phytochemical, Doctor of Philosophy, Department of Pharmacology, University College London, Department, United States Department of Agriculture, ISO 17025, Medical device, Agriculture, Pharmacology

They were also the first laboratory in the state of Vermont to be ISO/IEC 17025 accredited for cannabis testing.

Key Points: 
  • They were also the first laboratory in the state of Vermont to be ISO/IEC 17025 accredited for cannabis testing.
  • In addition, Bia Diagnostics is accredited to the Americans for Safe Access Cannabis standard, and participates in the AOAC Cannabis Analytical Sciences Program, ensuring the most up to date testing methodologies are used.
  • Through these efforts, Bia Diagnostics has the scientific expertise and regulatory experience necessary to assist adult use cannabis industry stakeholders in providing safe, compliant products, with fast turnaround times and accurate results.
  • You can find Bia Diagnostics participating in a variety of industry events and scientific conferences, including the upcoming Vermont Hemp and Cannabis Convention this month, where Dr. Farmer will be a featured speaker.

Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform

Retrieved on: 
Tuesday, May 17, 2022
Department, Disease, Doctor of Philosophy, Non-alcoholic fatty liver disease, NASH, AASLD, Patient, Lung cancer, University, Department of Pharmacology, University College London, Fatty liver disease, Algorithm, Molecular biology, Thyroid cancer, Biotechnology, Biochemistry, GlaxoSmithKline, Technology, Protein, Idiopathic pulmonary fibrosis, IPF, Diagnosis, AstraZeneca, Pharmaceutical industry, Medical imaging, Pharmacology

CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ --Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ --Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.
  • Dr. Wilde brings extensive experience in the development and launch of molecular-based diagnostics to Glympse as the company expands development of its protein activity biosensor assay platform.
  • "Jon brings a wealth of experience and strong track record in the field of late-stage molecular diagnostic development," said Caroline Loew, Ph.D., Chief Executive Officer of Glympse.
  • Using proprietary machine learning algorithms, the Glympse biosensor protease activity assay data is used to generate real-time information about the disease.

Alecia-Jane Twigger, Ph.D., Wins the Ruth A. Lawrence Investigator Award for Outstanding Contributions to Advancing Human Milk Science

Retrieved on: 
Wednesday, April 27, 2022
Woman, Research, Science, Doctor of Philosophy, Wellcome–MRC Cambridge Stem Cell Institute, Department of Pharmacology, University College London, Breast cancer, Seed, School, Infant, University, Neonatology, Academy, Breast milk, Biochemistry, Adult, Cell biology, Nature Communications, Cell, Conference, Pregnancy, Environment, Lactation, Strong Memorial Hospital, Federation, Travel, Awareness, Medicine, Obstetrics, Robert Twigger, University of Western Australia, Milk, Medical News Today, ABM, Department, FASEB, Dentistry, Industry, International Conference on Availability, Reliability and Security, Parity, Gynaecology, Medical News Schering, NICU, Experimental biology, Student, ScienceDaily, Risk, UHU, Pharmaceutical industry, Birth control, Dietary supplement, MD, Pharmacology, Chemistry, Innovation

VIENNA, April 27, 2022 /PRNewswire/ -- The International Conference on Human Milk Science and Innovation (ICHMSI) announced today that Dr. Alecia-Jane Twigger is the fourth recipient of theRuth A. Lawrence Investigator Award for Research in Human Milk Science.

Key Points: 
  • VIENNA, April 27, 2022 /PRNewswire/ -- The International Conference on Human Milk Science and Innovation (ICHMSI) announced today that Dr. Alecia-Jane Twigger is the fourth recipient of theRuth A. Lawrence Investigator Award for Research in Human Milk Science.
  • Established by ICHSMI in 2016, the Ruth A. Lawrence Investigator Award goes to outstanding contributors advancing human milk science and breastfeeding medicine through original research.
  • It is named in honor of Dr. Ruth A. Lawrence, MD, a pioneer in the field of lactation and breast milk.
  • The International Conference on Human Milk Science and Innovation, sponsored by Prolacta Bioscience, is the premier forum covering the latest in scientific and clinical research related to human milk.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Pharmaceutical industry, Residential care, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Health insurance, Residential care, Pharmaceutical industry, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Retrieved on: 
Wednesday, January 12, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Pleasure, Degenerative disease, CSO, Medication, Partner, College of Medicine, Hoffmann-La Roche, CEO, Roche, Department, IND, Department of Pharmacology, University College London, Standard of care, University of Saskatchewan academics, University, Â, Columbia Business School, Biophysical environment, Therapy, Concordia University, Hepatitis B, Tumor microenvironment, Company, Drug development, Cancer, Lead, Board, Management, Medicine, Pharmaceutical industry, Science, Pharmacology, Toxicology

Nirogy Therapeutics (Nirogy or the Company), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that it has appointed life science veteran Simon Pedder, Ph.D., as Chief Executive Officer (CEO) and to the Companys Board of Directors.

Key Points: 
  • Nirogy Therapeutics (Nirogy or the Company), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that it has appointed life science veteran Simon Pedder, Ph.D., as Chief Executive Officer (CEO) and to the Companys Board of Directors.
  • Dr. Pedder takes over the position from the founding CEO, Vincent Sandanayaka, Ph.D., who will be transitioning to the role of President and Chief Scientific Officer (CSO).
  • Dr. Pedder joins Nirogy from Athenex Pharmaceuticals, where he served as served as Chief Business and Strategy Officer.
  • Nirogy Therapeutics is a biotechnology company based in Boston, MA developing novel small molecules to target cellular transporters.

JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Physician, LSU Health Sciences Center Shreveport, Medical school, TSPO, Company, Janon, Research, School, SEC, Toxicology, Technology, Student, Heart, Culture, Security (finance), Medical education, Crave, Drug discovery, Methamphetamine, PAD, LCME, Private Securities Litigation Reform Act, Graduate school, Department of Pharmacology, University College London, Translocator protein, Faculty, Patient, MUD, Recycling, Liaison Committee (UK), Louisiana State University Shreveport, LARC, Louisiana, Education, Department, Graduate medical education, GME, LSU, Liaison Committee on Medical Education, VCU School of Allied Health Professions, FDA, School of Graduate Studies, Universiti Teknologi Malaysia, Sale, Nasdaq, Coronavirus Scientific Advisory Board (Turkey), Solution, ARCA, Risk, Drug, Pharmaceutical industry

"The misuse of meth has steadily increased over the past few years, resulting in an epidemic rivaling the opioid crisis.

Key Points: 
  • "The misuse of meth has steadily increased over the past few years, resulting in an epidemic rivaling the opioid crisis.
  • Unlike opioids, however, there is no known antidote for methamphetamine overdoses and no FDA-approved treatment for methamphetamine use disorder.
  • JanOne Inc. anticipates initiating a drug discovery program in 2022, with the goal of identifying a preclinical IND-candidate in 2023.
  • LSU Health Shreveport has strong community support, fostering a culture of diversity and inclusion that promotes mutual respect for all.